A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma.
Sponsor: Nexstar Pharmaceuticals
Listed as NCT00002093, this PHASE3 trial focuses on HIV Infections and Sarcoma, Kaposi and remains completed. Sponsored by Nexstar Pharmaceuticals, it has been updated 6 times since 2026, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Nexstar Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Boston, United States, Chicago, United States, Denver, United States, Houston, United States, Los Angeles, United States, Miami, United States, New York, United States, Palm Springs, United States, Portland, United States, San Francisco, United States and 2 more location s